Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Affiliations

• ¹ Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. [email protected].
• ² University of Kansas School of Medicine-Wichita, Wichita, KS, USA.
• ³ University of Victoria, Victoria, BC, Canada.
• ⁴ Kaiser Permanente Springfield Medical Center, Springfield, VA, USA.
• ⁵ University of Calgary, Calgary, AB, Canada.
• ⁶ Arkansas Gastroenterology, North Little Rock, AR, USA.
• ⁷ Louisiana Research Center, Shreveport, LA, USA.
• ⁸ Ochsner Clinic, New Orleans, LA, USA.
• ⁹ University of Florida, Gainesville, FL, USA.
• ¹⁰ Berry Consultants, LLC, Austin, TX, USA.
• ¹¹ Formerly of Rebiotix, Inc, Roseville, MN, USA.
• ¹² Rebiotix, Inc, Roseville, MN, USA.
• ¹³ Yale School of Medicine, New Haven, CT, USA.
• ¹⁴ PACT Gastroenterology Center, Hamden, CT, USA.